2,2-dimethyl-3-(4-methylpiperazin-1-yl)propanoic acid | 876343-22-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,2-dimethyl-3-(4-methylpiperazin-1-yl)propanoic acid
• 英文别名: 2,2-Dimethyl-3-(4-methylpiperazin-1-ium-1-yl)propanoate
• CAS: 876343-22-5
• 化学式: C₁₀H₂₀N₂O₂
• 分子量: 200.281
• InChiKey: CJPFOPAVOCAAFH-UHFFFAOYSA-N

物化性质

• 沸点：
  320.5±27.0 °C(Predicted)
• 密度：
  1.052±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,2-dimethyl-3-(1-piperidyl)propanoic acid 、 benzyl 2,2-dimethyl-3-(4-methylpiperazin-1-yl)propanoate 生成 2,2-dimethyl-3-(4-methylpiperazin-1-yl)propanoic acid
  参考文献：
  名称：

  Substituted pyrrolo[2.3-B]pyridines

  摘要：

  公式（I）所代表的化合物，或其立体异构体或药学上可接受的盐，是动物，包括人类中至少两种Abl，Aurora-A，Blk，c-Raf，cSRC，Src，PRK2，FGFR3，Flt3，Lck，Mek1，PDK-1，GSK3β，EGFR，p70S6K，BMX，SGK，CaMKII，Tie-2，IGF-1R，Ron，Ret和KDR激酶的抑制剂，用于治疗和/或预防各种疾病和病况，如癌症。

  公开号：

  US07465726B2

文献信息

• Amelioration of cataracts, macular degeneration and other ophthalmic diseases
  申请人：Matier L. William

  公开号：US20050131025A1

  公开（公告）日：2005-06-16

  Ophthalmically acceptable compositions used in arresting the development of cataract, presbyopia, macular degeneration and other retinopathies, glaucoma, uveitis and various corneal disorders are disclosed. The compositions are also useful as a prophylactic treatment to prevent or delay development of age-related ocular disorders, which include cataracts, presbyopia, glaucoma and macular degeneration. The compositions comprise a pharmaceutically acceptable carrier or diluent and at least one compound having the formula: where R 1 and R 2 are, independently, H or C 1 to C 3 alkyl; R 3 and R 4 are, independently C 1 to C 3 alkyl; and where R 1 and R 2 , taken together, or R 3 and R 4 , taken together, or both may be cycloalkyl; R 5 is H, OH, or C 1 to C 6 alkyl; R 6 is or C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R 7 is C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R 6 and R 7 , or R 5 , R 6 and R 7 , taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

  本发明涉及可用于阻止白内障、老视、黄斑变性和其他视网膜病变、青光眼、葡萄膜炎以及各种角膜疾病的眼科可接受的组合物。该组合物还可用作预防性治疗，以预防或延迟年龄相关的眼部疾病的发展，包括白内障、老视、青光眼和黄斑变性。该组合物包括一种药用可接受的载体或稀释剂和至少一种具有以下式子的化合物：其中R1和R2独立地为H或C1到C3烷基；R3和R4独立地为C1到C3烷基；而R1和R2一起取代，或R3和R4一起取代，或两者都可以是环烷基；R5为H、OH或C1到C6烷基；R6为C1到C6烷基、烯基、炔基或取代的烷基或烯基；R7为C1到C6烷基、烯基、炔基或取代的烷基或烯基，或者R6和R7，或者R5、R6和R7一起形成一个具有3到7个原子的环烷或杂环。
• Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases
  申请人：Matier William L.

  公开号：US20130131052A1

  公开（公告）日：2013-05-23

  Ophthalmically acceptable compositions used in arresting the development of cataracts or macular degeneration comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula: where R 1 and R 2 are, independently, H or C 1 to C 3 alkyl; R 3 and R 4 are, independently C 1 to C 3 alkyl; and where R 1 and R 2 , taken together, or R 3 and R 4 , taken together, or both may be cycloalkyl; R 5 is H, OH, or C 1 to C 6 alkyl; R 6 is or C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R 7 is C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R 6 and R 7 , or R 5 , R 6 and R 7 , taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

  眼科可接受的组合物，用于阻止白内障或黄斑变性的发展，包括一种药学可接受的载体或稀释剂和一种具有以下化学式的化合物：其中R1和R2分别为H或C1到C3烷基；R3和R4分别为C1到C3烷基；且其中R1和R2，一起取或R3和R4，一起取或两者都可以是环烷基；R5为H，OH或C1到C6烷基；R6为C1到C6烷基，烯基，炔基或取代的烷基或烯基；R7为C1到C6烷基，烯基，炔基或取代的烷基或烯基，或者其中R6和R7，或R5，R6和R7一起形成具有3到7个原子的碳环或杂环。
• Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
  申请人：Ahmed Saleh

  公开号：US20060211678A1

  公开（公告）日：2006-09-21

  Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.

  化合物式(I)所代表的化合物，或其立体异构体或药学上可接受的盐，是动物，包括人类体内至少两种Abl，Aurora-A，Blk，c-Raf，cSRC，Src，PRK2，FGFR3，Flt3，Lck，Mek1，PDK-1，GSK3β，EGFR，p70S6K，BMX，SGK，CaMKII，Tie-2，IGF-1R，Ron，Ret和KDR激酶的抑制剂，用于治疗和/或预防各种疾病和病症，如癌症。
• ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP1797054A2

  公开（公告）日：2007-06-20
• US7442711B2
  申请人：——

  公开号：US7442711B2

  公开（公告）日：2008-10-28